Yuri Maricich; Warren K. Bickel; Lisa A. Marsch; Kirstin M. Gatchalian; Jeffrey Botbyl; Hilary F. Luderer · 2020 · Current Medical Research and Opinion
Paper
OBJECTIVES: To evaluate the safety and efficacy of a digital therapeutic in treatment-seeking individuals with opioid use disorder (OUD) in an analysis of randomized clinical trial (RCT) data (ClinicalTrials.gov identifier: NCT00929253). METHODS: Secondary analysis of an RCT including 170 adults meeting DSM-IV criteria for OUD. Participants were randomized to 12-weeks of treatment-as-usual (TAU) or TAU plus a digital therapeutic providing 67 digital, interactive educational modules based on the Community Reinforcement Approach. TAU consisted of buprenorphine maintenance therapy, 30 min biweekly clinician interaction, and abstinence-based contingency management. Primary endpoints were treatment retention and abstinence (negative urine drug screen) during weeks 9-12 of treatment. Safety was assessed by evaluating adverse events. RESULTS:.42). CONCLUSIONS: A prescription digital therapeutic (PDT) in combination with buprenorphine therapy improves clinically significant patient outcomes including abstinence from illicit opioids and retention in treatment compared with treatment as usual.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Harsh Sah; Mahima Ramesh; C. Amrutha
Emanuele Arcà; Dorothea Heldt; Martina Smith
Linea Schmidt; Marc Pawlitzki; Bernhard Y. Renard; Sven G. Meuth; Lars Masanneck
Åsa Ingvar; Ibukun Oloruntoba; Maithili Sashindranath; Robert E. Miller; H. Peter Soyer; Pascale Guitera; Tony Caccetta; Stephen Shumack; Lisa M. Abbott; Chris Arnold; Craig Lawn; Alison Button‐Sloan; Monika Janda; Victoria Mar
Rebecca Brotherdale; Katherine Berry; Sandra Bucci
Akihiro Nomura
Source record